KeyCorp's favorable updates regarding loan growth and deposit management support the case for a potential 2Q2026 earnings ...
Moby summary of Culp, Inc.'s Q4 2026 earnings call ...
Vietnam Investment Review on MSN
Brii Bio phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...
From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results